Trending...
- How AI Exposed Major Flaws in the Foundation & Structure of Technology, Hardware & the Internet & Phinge's® Patented Netverse®, App-less Solution
- Only 7 Days Left for Early Bird Registration to the OpenSSL Conference 2025
- Bitcoin Mining: Your Path to Earning in the Crypto World
PHILADELPHIA, July 1, 2025 /PRNewswire/ -- Berger Montague, a national securities litigation law firm, is investigating potential securities fraud claims against Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). The firm is examining whether Hims & Hers, during the Class Period from April 29, 2025 through June 22, 2025 (the "Class Period"), violated federal securities laws by making false or misleading statements to investors.
Details of the Securities Fraud Investigation
On June 23, 2025, shares of Hims & Hers dropped more than 34% after Novo Nordisk revealed it terminated its partnership due to the Company's unauthorized marketing and sale of compounded semaglutide drugs. A complaint has been filed alleging material misstatements and omissions in violation of federal securities laws.
Deadline to Act
Investors have until August 25, 2025 to seek appointment as lead plaintiff in the class action lawsuit. Lead plaintiffs help direct the case and advocate on behalf of other harmed investors.
More on The PennZone
If you are a Hims & Hers investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865.
About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]
Caitlin Adorni
Berger Montague
(267) 764-4865
[email protected]
SOURCE Berger Montague
Details of the Securities Fraud Investigation
On June 23, 2025, shares of Hims & Hers dropped more than 34% after Novo Nordisk revealed it terminated its partnership due to the Company's unauthorized marketing and sale of compounded semaglutide drugs. A complaint has been filed alleging material misstatements and omissions in violation of federal securities laws.
Deadline to Act
Investors have until August 25, 2025 to seek appointment as lead plaintiff in the class action lawsuit. Lead plaintiffs help direct the case and advocate on behalf of other harmed investors.
More on The PennZone
- DATA BREACH ALERT: Edelson Lechtzin LLP is Investigating data privacy Claims on Behalf of TransUnion Customers
- Integris Composites Joins Pacific Future Forum in Tokyo
- BusinessRate Selects New Jersey Therapy & Life Coaching as Best Couselors
- IRL Investigations Combines Decades of Experience with Modern Digital Expertise
- New Leadership Model – Never Fire Anyone – Released Today
If you are a Hims & Hers investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865.
About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]
Caitlin Adorni
Berger Montague
(267) 764-4865
[email protected]
SOURCE Berger Montague
Filed Under: Business
0 Comments
Latest on The PennZone
- $5 - $20 Million in Sales for 2026; $25 - $40 Million for 2027 Projected with NASA Agreements; New MOU Signed to Improve Solar Tech in Space
- Costa Oil – 10 Minute Oil Change Opens 70th Location in Reed City, MI
- New Book: Cold War Sci-Fi Thriller Arrives Today
- BeeCool Bikes Unveils Next-Generation "Super Frame" with Bee Defender Series
- DEADLINE TOMORROW: Berger Montague Advises Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) Investors to Inquire About a Securities Fraud Class Action by August 29, 2025
- University of South Pacific and Battery Pollution Technologies Forge Strategic Partnership to tackle Battery End-of-Life Challenges in the Pacific
- Shincheonji Tanzania Church Holds Revelation Bible Exam with Local Pastors and Believers
- Portland Med Spa Expands Service Offerings with Latest Aesthetic Technologies
- Growth Acceleration via Strategic Reverse Split After $10 Million Acquisition for Concerts.com and TicketStub.com; AI Powered Sports/Entertainment Co
- Hollywood Casting Director's Book Hits #1 on Amazon Before Release
- OddsTrader Projects Three Potential Elimination Games in Week 1 of College Football
- Century Fasteners Corp. Exhibiting at the 2025 International Fastener Expo
- JKS Financial Strengthens Regional Presence with New Office in Sewickley
- Donors Join Forces to Support Center for Microbial Medicine at Children's Hospital of Philadelphia
- Canvas Cloud AI Launches to Transform Cloud Education From Memorization to Mastery
- The Squires Group Becomes a Workday Partner
- From Vernon Hills to Mensa Before Kindergarten
- Benchmark International Faciltd the Trans Between Total Sales & Marketing Inc and Retail Rex Capital
- PermianMuseum.com adds Interstellar Visitor Video Gallery
- SOBREO Elixirs Debut in New York City, Defining a New Era in Inclusive Hospitality